Australia's Clinuvel Pharmaceuticals jumps on preclinical study of peptide platform
12/01/2026 03:06
** Clinuvel Pharmaceuticals CUV.AX rises as much as 6.7% to A$13.48, highest since August 28, 2025 ** Co starts dosing in latest preclinical study of VLRX-L, its controlled-release liquid injectable peptide formulation platform ** Says VLRX-L platform designed to control release of peptides through flexible liquid dose ** Adds preliminary results expected in H2 2026 ** CUV rose 3.3% in 2025 (Reporting by John Biju in Bengaluru) ((John.Biju@thomsonreuters.com;))
Recent news on Clinuvel Pharmaceuticals
See all newsBrief: Clinuvel Pharmaceuticals Announces Strategic Reorganisation To Refocus On U.S. Markets
Brief: Clinuvel Pharmaceuticals Ltd's ADS To Commence Trading On Nasdaq
Brief: Clinuvel Pharmaceuticals Says Scenesse Approved For EPP In Canada
Australia's Clinuvel Pharmaceuticals rises on Canada nod for phototoxicity prevention drug
Brief: Clinuvel Pharmaceuticals Updates On Level II ADR Upgrade, Nasdaq Uplist